Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

O. Vondálová Blanářová, B. Šafaříková, J. Herůdková, M. Krkoška, S. Tománková, Z. Kahounová, L. Anděra, J. Bouchal, G. Kharaishvili, M. Král, P. Sova, A. Kozubík, A. Hyršlová Vaculová,

. 2017 ; 12 (11) : e0188584. [pub] 20171128

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18016220

Grant support
NV15-28628A MZ0 CEP Register

Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016220
003      
CZ-PrNML
005      
20180515104015.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0188584 $2 doi
035    __
$a (PubMed)29182622
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vondálová Blanářová, Olga $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic.
245    10
$a Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10 / $c O. Vondálová Blanářová, B. Šafaříková, J. Herůdková, M. Krkoška, S. Tománková, Z. Kahounová, L. Anděra, J. Bouchal, G. Kharaishvili, M. Král, P. Sova, A. Kozubík, A. Hyršlová Vaculová,
520    9_
$a Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.
650    _2
$a amantadin $x analogy a deriváty $x farmakologie $7 D000547
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a protein Bid $x metabolismus $7 D051023
650    _2
$a kaspasa 10 $x metabolismus $7 D053455
650    _2
$a cisplatina $x farmakologie $7 D002945
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a organoplatinové sloučeniny $x farmakologie $7 D009944
650    _2
$a nádory prostaty $x metabolismus $x patologie $7 D011471
650    _2
$a protein TRAIL $x metabolismus $7 D053221
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šafaříková, Barbora $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic. Department of Animal Physiology and Immunology, Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Herůdková, Jarmila $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic. Department of Animal Physiology and Immunology, Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Krkoška, Martin $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic. Department of Animal Physiology and Immunology, Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Tománková, Silvie $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic.
700    1_
$a Kahounová, Zuzana $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
700    1_
$a Anděra, Ladislav $u Institute of Biotechnology, Czech Academy of Sciences, v.v.i., Praha, Czech Republic.
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Král, Milan $u Department of Urology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Sova, Petr $u Platinum Pharmaceuticals, a.s., Brno, Czech Republic.
700    1_
$a Kozubík, Alois $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic. Department of Animal Physiology and Immunology, Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Hyršlová Vaculová, Alena $u Department of Cytokinetics, Institute of Biophysics, Czech Academy of Sciences, v.v.i., Brno, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 11 (2017), s. e0188584
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29182622 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515104149 $b ABA008
999    __
$a ok $b bmc $g 1299844 $s 1013060
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 11 $d e0188584 $e 20171128 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV15-28628A $p MZ0
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options